Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Same ones Brendan told us about 3 months ago?
TDA Contact Info for ENTI Update
Supposedly from the office of The President of TDA
Daniel at 888-723-8504 x207558
This is from TWO MONTHS ago.............
Any TDA trader get more info when our shares are going to be tradeable?
Due to the risky nature with new issues and OTC/penny stocks, DTC no longer automatically makes new issues eligible for electronic service. They must work with the company's agent on legally getting the new shares eligible, otherwise they must receive physical certificates from the agent. This ensures the legality of the new shares after receiving pressure from the SEC over the last few years. Once DTC has the shares either in electronic format or in certificate form, we will update our positions. Please contact us again if you have any additional questions.
Sincerely,
Derek Whitehill
Apex Corporate Actions and Dividends, TDA
Division of TD Ameritrade, Inc.
You're a postman and might go postal
TDA Contact Info for ENTI Update
Supposedly from the office of The President of TDA
Daniel at 888-723-8504 x207558
Very Glad Tony did the right thing and pushed this back
This has been an absolute nightmare and harder for everyone than it should have been
That the shares are not DTC eligible yet?
So you are telling the truth but TDA and Etrade are lying to 100s of investors
*Shaking his head*
I would suggest listening to CEO podcast before The Big Biz Show
I didnt and I apologize for posting without doing so
Here is the CEO podcast
http://www.encountertech.com/
Here is the Big Biz Show
http://bigbizshow.com/
So my broker keeps telling me ENTID not DTC eligible but then I see this announcement from 4/29
THIS NSCC OTC IMPORTANT NOTICE IS NOW AVAILABLE ON THE NSCC WEB SITE.THE WEB SITE WWW.DTCC.COM IS PASSWORD PROTECTED AND IS OPEN TO ALL FULL-SETTLING MEMBERS OR OTHER NSCC PARTICIPANTS. FIRMS THAT WANT ACCESS TO THE NOTICES OF CHANGES TO THE LIST OF OTC CLEARED SECURITIES SHOULD CALL THEIR NSCC ACCOUNT MANAGER AT 800-422-0582 TO OBTAIN THE APPROPRIATE INFORMATION FOR ACCESS.
DELETE 29259J105 ENTI ENCOUNTER TECHNOLOGIES
INC COM STK (CO)
XNAS
ADD 29259J303 ENTID ENCOUNTER TECH INC NEW
COM STK (CO)
XNAS 04/29/2011
Why would Etrade and TDA and Sharebuilder be flat out lying to their customers then jimblob? Why on EARTH would they be ALL wrong and you are right???????????
Thats true I am just disgusted over this entire thing
Shares still showing as N/A
And everyone from the company to my broker is blaming the other for the issues
Then we have people flat out lying on this site stating they are trading this Non-DTC eligible stock
I sent a message about contacting lawyers next on this issue to TDA and then supposedly I received a voicemail from the President's office of TDA - So I will be calling in the AM - Should be a funny conversation - will try my best for TDA customers to get as much info as possible
Tony talked about PTEL and Musicmatrix.com but ENTI/D was quietly removed
Can anyone say red-headed stepchild?
I can
No one has posted in 15 days
I saw it
So I posted it
Shoot Me
GERN Just One Stock: The Biopharma Veteran Facing a Landmark Stem Cell Trial
http://seekingalpha.com/article/249488-just-one-stock-the-biopharma-veteran-facing-a-landmark-stem-cell-trial?source=yahoo
Robert Lawton is managing partner of Catoosa Fund, a long/short hedge fund. He began his career in the industry more than 20 years ago at Alex. Brown & Sons.
If you could only hold one stock position in your portfolio (long or short), what would it be?
Long, Geron Corp. (GERN).
Tell us more about the company behind the stock.
Geron is a small-cap (currently around $500 million) biotech with two primary focuses: oncology and Human Embryonic Stem Cell (HESC)-based therapies.
In oncology, Geron has a broad IP portfolio which include a large number of patents targeting what may prove to be a worthy area of pursuit in the fight against cancer: telomerase. Telomerase was discovered by two early Geron collaborators who were awarded the Nobel Prize for medicine in 2009 for their discovery. Geron currently holds over 300 domestic and international patents related to telomerase as a potential cancer target.
Geron's other, slightly less crowded, and certainly more controversial focus relates to Human Embryonic Stem Cells (HESCs) as a potential remedy for a myriad of maladies, from Alzheimer's to paralysis. They have first mover advantage in the field and the benefit of being unreliant on the federal government for research dollars toward their pursuit, thereby sidestepping to some degree the controversy surrounding federal funds supporting this research.
In 2010, the FDA allowed Geron to proceed with the first ever clinical trials of HESCs in humans. I can't possibly overemphasize the importance of this historic trial. The primary endpoint of the Phase I is safety, although the secondary endpoint will be to determine efficacy. If safety is demonstrated along with even a modicum of efficacy? In my view, it will be considered one of the biggest scientific breakthroughs in the history of medicine.
How does your choice reflect your fund's investment approach?
We are a long/short hedge fund focusing primarily on domestic equities in all range of capitalization and sectors. We try to isolate situations where there is likely to be a relatively near-term catalyst to propel the shares in either direction.
I prefer to invest on the long side in companies with strong balance sheets, first mover advantage and/or dominant positions among their peers, and management I'm comfortable with. In the case of Geron, it's a $5 stock with a strong cash position, no debt, and are in the midst of a very high-profile clinical testing phase.
How much is your selection based on Geron's industry, as opposed to a pure bottom-up pick?
The biotech field, as you probably know, is littered with the wreckage of considerably more failures than successes. For every Dendreon (DNDN) or HGSI there are infinitely more Medivations (MDVN) or deCODE genetics. The potential to cure illnesses or alleviate suffering, coupled with the resulting "blockbuster" revenue streams accompanying such a success, can be quite seductive.
What I like about Geron is they have a very broad and deep IP/patent portfolio, strong cash position and, as excruciatingly slow as it has been waiting for results, I believe they are in the home stretch, at least regarding the HESC component of their business. If successful? I think the long-term upside is incalculable.
How is Geron positioned with regard to competitors?
Geron has been referred to - in a really fascinating 60 Minutes piece which I encourage any potential investor to watch - as "the Microsoft (MSFT) of the stem cell industry."
They are the 600-pound gorilla in the space, for now, conducting the first in-man, very high profile clinical trial. It's really somewhat of a binary event for the science, in my view. They will likely succeed or fail in a very big way, and advance or set back the science of HESCs forever.
The good news, from an investment standpoint, is that in the event the HESC side of their business fails spectacularly, they still have a formidable oncology department.
How does the stock's valuation compare to its competitors?
The market cap is around $500 million, nearly half of which is cash, with zero debt. Their burn rate is around $50 million a year, so they are pretty well funded for the near term, having recently completed a $100 million secondary.
The stock has largely been dead money for the past 12 months, with a tight trading range between roughly $4.50 & $6.50/share. I expect that range will end this year, somewhat dramatically.
In terms of other peers in the area, what do you think about competition from bigger companies like Cephalon (CEPH) - which like GERN does oncology work along with recent agreements to develop stem-cell therapeutics? Or smaller StemCells Inc. (STEM)? Is it about first-mover advantage in this area?
I think with regard to HESCs, they are peerless due to their IP and first-mover advantage in the field. Remember, they have been at this since the beginning and were early to finance and capture IP rights.
Regarding oncology... they are no match for deeper pocketed big pharma but, again, their telomerase focus, if successful, separates them from the pack, due to their broad patent portfolio associated with it.
Does your view differ from the consensus sentiment on GERN?
Geron has no shortage of critics, myself occasionally included among them. Investors and the few analysts who do cover the stock seem to be (understandably) frustrated.
The company recently completed a secondary priced well below the market at the time. I must confess I was gobsmacked by both the timing and pricing of the offering, but the old adage in the biotech space is "raise money when you can, not when you need to." Overall, I think most investors are frustrated with the arguably "glacial" pace of Geron's journey from lab to clinic to market.
Worth noting, however: It was only in 1998 that stem cells were first discovered. Today they are being tested in humans with "Patient A" receiving an injection in October. In the broader view of time, a few quarters or years is insignificant in light of the larger backdrop of history and what is at stake.
Simply put: Imagine if a previously hopelessly paralyzed individual has any mobility restored? In addition to providing hope to millions, I believe it will go a long way toward silencing the critics of this controversial endeavor. Regardless of where you sit on the political or ethical debate, it's hard to argue with someone confined to a wheelchair for life that HESCs which were previously destined for a dumpster shouldn't be used to restore their mobility because of the Bible.
Separately, regarding analyst coverage: Thanks to the Internet and the laws of the land, huge quantities of information are easily accessible to anyone who seeks it and are in no way proprietary to the landscape of Wall Street anymore. Point being? In my view, the vast majority of "Wall Street Analysts" are worthless at best and dangerous at worst. The stock is largely uncovered - for now - and that's fine by me. My experience has been that the analysts usually pile on well after the smart money has taken a position (or exited).
Does the company's management play a role in your selection?
Always. I'm comforted by the fact that the CEO of Geron, Dr. Thomas Okarma, holds both an M.D. & a Ph.D. from Stanford and is a graduate of the executive program of the Stanford Graduate School of Business. He appears to be a scientist first and a businessman second. I'm fine with that. Even the company's director of investor relations has a Ph.D. in the field.
What catalysts, near-term or long-term, could move the stock significantly?
As discussed, the first ever in-man HESC trial is likely to be a closely watched major catalyst for the shares. If there have been no major safety issues along with even a minor improvement? The stock should move both abruptly and significantly.
What could go wrong with your pick?
If safety issues arise leading to a halting of the trial? The stock will likely get clobbered, at least initially. If it shows negligible efficacy but is generally well tolerated? I think the stock gets clipped pretty hard there as well.
The same is true if their oncology pursuit fails miserably (safety issues) or simply shows no efficacy, but this is likely years away and they have a pretty deep bench in that regard.
Frankly, I think the company is likely be acquired long before any phase IIIs are completed. I consider the risk/reward at around $5/share to be roughly 2 points downside vs. 5 to 10 points upside. I'll take those odds any day of the week.
This patience issue seems to be a key one for Geron. It's come under fire in the past for heavily diluting shareholders on positive results; what's the risk that continues even in the case of a successful trial - since that would bear heavily on the stock price?
Dilution has been frustrating but I'm still in the "raise money when you can, not when you need to" camp. The bottom line is: If they produce substantive results in the clinics? The stock goes much higher and they are welcome to come back to us for further R&D funding (and therefore dilution).
Failing that? They better not come back, hat in hand, anytime soon or I'd view that as troubling.
Thanks, Robert, for sharing your choice with us.
Thank you.
Disclosure: Long GERN.
Read more Just One Stock interviews »
If you are a fund manager and interested in doing an interview with us on just one stock or ETF position you'd hold, please email us at Just One Stock.
About the author: Robert Lawton
Robert Lawton began his career in finance in 1990 at the first Investment Bank in the United States, Alex. Brown & Sons. He became a Licensed Registered Representative in 1995 and has over 15 years of experience as a Vice-President of NASD & NYSE Member Firms. Mr. Lawton has served as... More Company: Catoosa Fund L.P.
If you're scared buy a dog
Sell On News - People are Idiots down 25% already
My apologies to Mr Young the party was a surprise....The Cat is out of the bag now!!! LMAO!!
Hey Old_School - Punk - Smell That
Smells like a GREEN Day today for HNSS
Yes paying down your Debt by 84% is always a good thing
$HNSS too!!!
NEWS OUT
ELITE PHARMACEUTICALS ANNOUNCES EXCHANGE OF SERIES D CONVERTIBLE PREFERRED SECURITIES FOR COMMON,
ELIMINATEs FUTURE DIVIDENDS
NORTHVALE, N.J. - May 24, 2011 -Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) today announced that all of the outstanding shares of its Series D 8% Convertible Preferred Stock (the "Series D") has been converted into the Company's common stock, pursuant to the election of the holders of the Series D. This eliminates the Company's obligation to pay $720,000 in annual dividends and eliminates the associated administrative costs. The Company now has 243,363,531 shares of common stock outstanding.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has three approved ANDA's partnered with TAGI Pharma, with an additional ANDA currently under review by the FDA. Elite's lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. Elite undertakes no obligation to update any forward-looking statements.
Correct in my opinion you bought diluted shares
I mean who in their right mind sold today let alone 243 million shares worth
Most times things are exactly as they appear.
To constanly state as to not know where the 243 million shares that were traded today came from would just be naive.
In My Opinion of course I have no idea where the shares came from either.
So my only assumption is people who are allowed to trade shares which are Zecco and paperholders???? Anyone else?
I mean who in there right mind would sell at .0004 before the 1 for 1 PTEL split???? Right????
So I agee to state they are coming from Zecco shareholders is shortsighted since the only answer is dilution.
In my opinion
240 million worth of paper traders today?
Doubt it.
238 million in volume but besides Zecco customers (supposedly) no one can trade.
So where are these shares that people are "buying" coming from?
This Bad Boy Isnt gonna run this week
Global Earth Energy Inc. provides renewable energy solutions
So why are they buying coal again?........
That is a good point about Zecco and DTC
Wow I am the last post from a week ago?
Was it in fact ENTI shares or PTEL shares?
Sully said Pegasus and that they were compensated the 2.35 million shares
Yeah I picked up on that to
They certainly will correct next week
They even invited Tony out to the set of the show
They also said they will be covering this company for the next several months so 2 million is certainly a drop in the bucket but I wonder if it was PTEL or ENTI
A little over 2 million shares as was just stated even though the Big Biz guy stuttered while he said it so I just heard 2 and million - maybe he said 2230000?
TDA Update still sticking by DTC defense
Mr. XXXXX,
Thank you for your email. We do apologize for any inconvenience that you are experiencing. The situation first arose because the agent was working with our depository, Depository Trust Company (DTC), to make the security eligible. Since ENTID does not meet the full requirements, it was flagged as not being DTC eligible. Here is a link that is not affiliated with TD Ameritrade that will explain what it takes to become DTC eligible:
http://gopublicpros.com/benefitsofgoingpublic.html
You will find the DTC eligibility half way through the page. The new physical certificates have to be delivered to us before we can update the accounts held at TD Ameritrade. Typically, the timeframe is between 4-6 weeks, but it can occur sooner, or even later than that. There is currently no indication as to when this will be completed. Please send us an email with additional questions or concerns.
TD AMERITRADE is not responsible for the claims or representations made by the above Web site. We cannot guarantee the quality or suitability of any content found there. TD AMERITRADE does not endorse or recommend the products or services of any company mentioned on this site.
Sincerely,
Matias Eisenhauer
Apex Corporate Actions and Dividends, TDA
Division of TD Ameritrade, Inc.
If you live in Tampa call SG and he will give you a tour of the call center!!
I spoke to him earlier this year and was flying out to see everything
He welcomed and was excited to have a shareholder tour the company
Are Zecco customers really able to trade their forward split shares??????????
I am about to call my lawyer and bring a class action against TDA as this is getting beyond ridiculous
Anyone with a Zecco account that is credible (At least 20+ followers) please private IM me as I am dead serious about this.
There were two "reorginization"s listed in my account profile but both had a 0.00 charge that was TDA
Per TDA on the N/A Status
Mr. XXXXX,
Thank you for your email regarding ENTI - Encounter Technologies. Our depository has informed us that the new CUSIP was not made DTC eligible. DTC will be exiting the shares to us and we will either have to hold the physical shares or locate a depository that will accept these shares. In the meantime, your shares are being held in a contra position under CUSIP 29259J964 to reflect the post-split shares. Once we receive the new shares, we will process the positions to reflect the new shares as long as there are no restrictions.
If you have any further questions or concerns, please feel free to contact us.
Sincerely,
Travis Ho
Apex Corporate Actions and Dividends, TDA
Division of TD Ameritrade, Inc.